1. Home
  2. CE vs BLLN Comparison

CE vs BLLN Comparison

Compare CE & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celanese Corporation

CE

Celanese Corporation

SELL

Current Price

$48.70

Market Cap

5.5B

Sector

Industrials

ML Signal

SELL

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

SELL

Current Price

$97.62

Market Cap

4.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CE
BLLN
Founded
1918
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.6B
IPO Year
2004
2025

Fundamental Metrics

Financial Performance
Metric
CE
BLLN
Price
$48.70
$97.62
Analyst Decision
Buy
Buy
Analyst Count
18
8
Target Price
$63.39
★ $128.29
AVG Volume (30 Days)
★ 1.4M
575.5K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
★ 0.25%
N/A
EPS Growth
23.62
★ 103.40
EPS
★ 2.21
0.81
Revenue
★ $9,544,000,000.00
$305,112,000.00
Revenue This Year
$4.47
$51.61
Revenue Next Year
N/A
$24.03
P/E Ratio
★ $22.16
$118.64
Revenue Growth
N/A
★ 99.97
52 Week Low
$35.39
$61.96
52 Week High
$70.70
$150.44

Technical Indicators

Market Signals
Indicator
CE
BLLN
Relative Strength Index (RSI) 49.61 36.40
Support Level $43.28 $89.26
Resistance Level $49.63 $97.18
Average True Range (ATR) 2.19 6.32
MACD -0.06 -1.85
Stochastic Oscillator 33.90 12.62

Price Performance

Historical Comparison
CE
BLLN

About CE Celanese Corporation

Celanese is a global specialty chemicals manufacturer. It operates in two segments: acetyl chain, and engineered materials. Acetyl chain profitability is exposed to commodity-linked raw materials and product pricing spreads. Engineered materials converts basic chemicals into higher-margin specialty polymers and compounds engineered for specific customer applications in automotive, medical, electronics, and industrial end markets.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: